Investor Presentaiton

AROA PRODUCT RANGE ADDRESSES A WIDE RANGE OF APPLICATIONS AND LARGE ADDRESSABLE MARKETS Brand name Use case Endoform Natural & Antimicrobial Stalled complex wounds FY'18 FY'19 FY'20 FY'21 FY'22 FY23 US TAM (USD) Sales Launch Channel New Pipeline Existing Commercial Products Ovitex Myriad Ovitex PRS Symphony TBC Hernia Dermal & implantable Reconstruction Licensed to TELA Bio solely for Breast Surgery Complex wounds & Limb salvage Dead Space Management Sources: 1 & 5 SmartTRAK Biomed GPS data 2020, 2. DRG Millennium Research data, Hernia Repair Devices, 2020, 3 AROA management estimates, 4. DRG Millennium Research, Breast Implants & Reconstructive devices, 2018. 6. Based on current project timeline but remains subject to changes in circumstances and regulatory clearances. *Note: Symphony requires a new reimbursement code, whereas all other products fall under existing reimbursement codes $78m1 AROA FY'13 $845m² TelaBio FY'17 $200m³ AROA FY'20 $463m4 TelaBio FY'20 $1.15b5 AROA FY'216 TBD AROA FY'23/246 Product Development Regulatory clearance Reimbursement* Commercial sales TM AROA 15

View entire presentation